Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.63 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21724681 | 1.00 | PLA2G2C (0.63) | PLA2G2CPLA2G10FAAHMEN1KMT2A | |
| SCHEMBL21724501 | 1.00 | PLA2G2C (0.63) | PLA2G2CPLA2G10FAAHMEN1KMT2A | |
| SCHEMBL27960067 | 1.00 | PLA2G2C (0.63) | PLA2G2CPLA2G10FAAHMEN1KMT2A | |
| SCHEMBL6041046 | 1.00 | PLA2G2C (0.63) | PLA2G2CPLA2G10FAAHMEN1KMT2A | |
| SCHEMBL11024007 | 1.00 | PLA2G2C (0.63) | PLA2G2CPLA2G10FAAHMEN1KMT2A | |
| SCHEMBL21724603 | 1.00 | PLA2G2C (0.63) | PLA2G2CPLA2G10FAAHMEN1KMT2A | |
| SCHEMBL20876509 | 1.00 | PLA2G2C (0.63) | PLA2G2CPLA2G10FAAHMEN1KMT2A | |
| SCHEMBL21724244 | 0.98 | PLA2G2C (0.60) | PLA2G2CPLA2G10FAAHMEN1KMT2A | |
| SCHEMBL27889998 | 0.92 | TERT (0.56) | PLA2G2CFAAHKMT2APPARGPPARD | |
| SCHEMBL25173449 | 0.90 | PLA2G2C (0.49) | PLA2G2CPLA2G10FAAHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869930-B1 | Acylated insulin | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | claimed |
| US-6011007-A | ZN2+ COMPLEX. | NOVO NORDISK A/S (DK) | 2000-01-04 | — | — | US | claimed |
| US-10195254-B2 | Myristoylated leptin-related peptides and uses thereof | ALBANY MEDICAL COLLEGE (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170312340-A1 | MYRISTOYLATED LEPTIN-RELATED PEPTIDES AND USES THEREOF | ALBANY MEDICAL COLLEGE (US) | 2017-11-02 | — | — | US | disclosed |
| EP-3180021-A2 | MYRISTOYLATED LEPTIN-RELATED PEPTIDES AND USES THEREOF | Albany Medical College (US) | 2017-06-21 | — | — | EP | disclosed |
| CN-106794225-A | Leptin related peptide of myristoylation and application thereof | 奥尔巴尼医学院 | 2017-05-31 | — | — | CN | disclosed |
| WO-2016025459-A2 | MYRISTOYLATED LEPTIN-RELATED PEPTIDES AND USES THEREOF | ALBANY MEDICAL COLLEGE (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20060030518-A1 | Acylated insulin | SCIAPS, INC. | 2006-02-09 | — | — | US | disclosed |
| US-6869930-B1 | Acylated insulin | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| US-20040110664-A1 | Acylated insulin | HAVELUND SVEND (DK) | 2004-06-10 | — | — | US | disclosed |
| EP-1132404-A2 | Acylated insulin | NOVO NORDISK A/S (DK) | 2001-09-12 | — | — | EP | disclosed |
| EP-0792290-B1 | ACYLATED INSULIN | NOVO NORDISK AS (DK) | 2001-08-29 | — | — | EP | disclosed |
| EP-0792290-A1 | ACYLATED INSULIN | NOVO NORDISK A/S (DK) | 1997-09-03 | — | — | EP | disclosed |
| US-5432267-A | Inhibits tumor necrosis factor derivation by endotoxin | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1995-07-11 | — | — | US | disclosed |
| WO-1995007931-A1 | ACYLATED INSULIN | NOVO NORDISK A/S (DK) | 1995-03-23 | — | — | WO | disclosed |
| EP-0563908-A1 | Amino sugar derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030518-A1 | Acylated insulin | INSR, BCAT1, SLC1A5 | PLA2G2C 538/4885PLA2G10 278/4885FAAH 3262/4885 |
| US-20040110664-A1 | Acylated insulin | INSR, BCAT1, INSRR | PLA2G2C 454/4885PLA2G10 263/4885FAAH 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.